Abstract
Hepatitis C virus (HCV) infection is a major problem associated with hemodialysis. The extent of liver damage in hemodialysis patients with chronic HCV infection has not been thoroughly documented. The aim of this study was to evaluate liver damage of hemodialysis patients infected with HCV. A total of 233 hemodialysis patients were categorized into two groups at entry: group X, 80 positive for serum HCV RNA, and group Y, 153 negative for serum HCV RNA. All were tested for serum alanine aminotransferase (ALT) serially from 1989 to 1998, and serum hyaluronic acid (HA), serum type-IV collagen (IV-C), platelet counts, and ultrasonographic examination of the liver was done in 1998. In group X, 61.3% had continuously abnormal ALT levels for over six months followed by normal ALT levels. Of the group X patients, 11.3% had abnormal ALT levels in 1998, and in three, hepatocellular carcinoma occurred. Mean HA and IV-C levels in group X (648.8 and 188.7 ng/ml, respectively) were significantly higher than in group Y (213.1 and 165.5 ng/ml, respectively) (P < 0.05). Ultrasonographic findings significantly correlated with serum HA level and platelet counts and showed significantly more abnormalities in group X than in group Y (P < 0.05). From these findings, a combined examination with ultrasonography and serum fibrogenesis markers is useful for detection of liver damage in hemodialysis patients with HCV viremia.
Similar content being viewed by others
REFERENCES
Hayashi J, Nakashima K, Kajiyama W, Noguchi A, Morofuji M, Maeda Y, Kashiwagi S: Prevalence of antibody to hepatitis C virus in hemodialysis patients. Am J Epidemiol 134:651–657, 1991
Sakamoto N, Enomoto N, Marumo F, Sato C: Prevalence of hepatitis C virus infection among long-term hemodialysis patients: Detection of hepatitis C virus RNA in plasma. J Med Virol 39:11–15, 1993
Hayashi J, Yoshimura E, Nabeshima A, Kishihara Y, Ikematsu H, Hirata M, Maeda Y, Kashiwagi S: Seroepidemiology of hepatitis C virus infection in hemodialysis patients and the general population in Fukuoka and Okinawa, Japan. J Gastroenterol 29:276–281, 1994
Hayashi J, Nakashima K, Yoshimura E, Kishihara Y, Ohmiya M, Hirata M, Kashiwagi S: Prevalence and role of hepatitis C viraemia in haemodialysis patients in Japan. J Infect 28:271–277, 1994
Roth D: Hepatitis C virus: The nephrologist's view. Am J Kidney Dis 25:3–16, 1995
van der Poel CL, Cuypers HT, Reesink HW: Hepatitis C virus six years on. Lancet 344:1475–1479, 1994
Vitale C, Tricerri A, Marangella M, Vacha GM, Giorcelli G, Marini C, Molinaro G, Cosseddu D, Linari F: Epidemiology of hepatitis C virus infection in dialysis units: First versus second-generation assays. Nephron 64:315–316, 1993
Caramelo C, Ortiz A, Aguilera B, Porres JC, Navas S, Marriott E, Alberola ML, Alamo C, Galera A, Garron MP, Gonzalez-Parra E, Fernandez de Gabriel MV, Oliva H, Carreno V: Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 22:822–828, 1993
Chan TM, Lok AS, Cheng IK, Chan RT: Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assays. Hepatology 17:5–8, 1993
Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y, Etoh Y, Ikematsu H, Kashiwagi S: Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology 25:697–701, 1997
Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa K, Kashiwagi S: Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 90:794–799, 1995
Hayashi J, Yoshimura E, Kishihara Y, Yamaji K, Etoh Y, Ikematsu H, Kashiwagi S: Hepatitis C virus RNA levels determined by branched DNA probe assay correlated with levels assessed using competitive PCR. Am J Gastroenterol 91:314–318, 1996
Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Sato K, Tsuda F, Miyakawa Y, Mayumi Y: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 73:673–679, 1992
Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, Chan SW, Chayama K, Chen DS, Choo QL, Colombo M, Cuypers HTM, Date T, Dusheiko GM, Esteban JI, Fay O, Hadzyannis SJ, Han J, Hatzakis A, Holmes EC, Hotta H, Houghton M, Irwine B, Kohara M, Kolberg JA, Kuo G, Lau JYN, Lelie PN, Maertens G, McOmish F, Miyamura T, Mizokami M, Nomoto A, Prince AM, Reesink HW, Rice C, Roggendorf M, Schalm SW, Shikata T, Shimotohno K, Stuyver L, Trepo C, Weiner A, Yap PL, Urdea MS: A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321–1324, 1994
Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, Wilber J: Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 31:2679–2682, 1993
Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF: Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: A longitudinal study. J Clin Ultrasound 21:303–308, 1993
Alberti A, Morsica G, Chemello L, Cavalletto D, Noventa F, Pontisso P, Ruol A: Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 340:697–698, 1992
al-Wakeel J, Malik GH, al-Mohaya S, Mitwalli A, Baroudi F, el Gamal H, Kechrid M: Liver disease in dialysis patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 11:2265–2268, 1996
Wolf PL, Williams D, Coplon N, Coulson AS: Low aspartate transaminase activity in serum of patients undergoing hemodialysis. Clin Chem 18:567–568, 1972
Warnock LG, Stone WJ, Wagner C: Decreased aspartate transaminase ("SGOT") activity in serum of uremic patients. Clin Chem 20:1213–1216, 1974
Cohen GA, Goffinet JA, Donabedian RK, Conn HO: Observations on decreased serum glutamic oxaloacetic transaminase (SGOT) activity in azotemic patients. Ann Intern Med 84:275–280, 1976
Crawford DR, Reyna RS, Weiner MW: Effects on in vivo and in vitro dialysis on plasma transaminase activity. Nephron 22:418–422, 1978
Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, Yokozeki K, Kobayashi S, Irie Y: Hypoaminotransferasemia in patients undergoing long-term hemodialysis: Clinical and biochemical appraisal. Gastroenterology 109:1295–1300, 1995
Bailey GL, Katz AI, Hampers CL, Merrill JP: Alternations in serum enzymes in chronic renal failure. JAMA 213:2263–2265, 1970
Heaf JG: Liver function tests and pyridoxine levels in uremia. Nephron 30:131–136, 1982
Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G: Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1:414–416, 1986
Ishibashi K, Kashiwagi T, Ito A, Tanaka Y, Nagasawa M, Toyama T, Ozaki S, Naito M, Azuma M: Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C. Hepatology 24:27–31, 1996
Yabu K, Kiyosawa K, Mori H, Matsumoto A, Yoshizawa K, Tanaka E, Furuta S: Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 29:474–479, 1994
Kosugi S, Imai Y, Kurata Y, Tomiyama Y, Shiraga M, Honda S, Nishikawa M, Yonezawa T, Kanakura Y, Matsuzawa Y: Platelet-associated IgM elevated in patients with chronic hepatitis C contains no anti-platelet autoantibodies. Liver 17:230–237, 1997
Ono K, Uchino F: Formation of amyloid-like substance from beta-2–microglobulin in vitro. Role of serum amyloid P component: A preliminary study. Nephron 66:404–407, 1994
Yuki N, Hayashi N, Matsushita Y, Tabata T, Inoue T, Fusamoto H, Kamada T: Hepatitis C biochemical remission and viral replication in haemodialysis patients. J Med Virol 48:242–246, 1996
Okuda K, Hayashi H, Yokozeki K, Irie Y: Destruction of hepatitis C virus particles by haemodialysis. Lancet 347:909–910, 1996
Hayashi H, Okuda K, Yokosuka O, Kobayashi S, Yokozeki K, Ohtake Y, Irie Y: Adsorption of hepatitis C virus particles onto the dialyzer membrane. Artif Organs 21:1056–1059, 1997
Furusyo N, Hayashi J, Ariyama I, Sawayama Y, Etoh Y, Shigematsu M, Kashiwagi S: Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol 95:490–496; 2000
DuBois DB, Gretch D, dela Rosa C, Lee W, Fine J, Blagg CR, Corey L: Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: Gender-related differences in viral load. Am J Kidney Dis 24:795–801, 1994
Hayashi J, Kawakami Y, Nabeshima A, Kishihara Y, Furusyo N, Sawayama Y, Kinukawa N, Kashiwagi S: Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. Dig Dis Sci 43:384–391, 1998
Akiba T, Kawaguchi Y, Kuroda M, Nihei H, Hidai H, Yanakawa M, Yamazaki C, Marumoto F: Survey on hepatitis C virus infection in Japanese dialysis population. J Jpn Soc Dial Ther 27:77–82, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Furusyo, N., Hayashi, J., Kanamoto-Tanaka, Y. et al. Liver Damage in Hemodialysis Patients with Hepatitis C Virus Viremia: A Prospective 10-Year Study. Dig Dis Sci 45, 2221–2228 (2000). https://doi.org/10.1023/A:1026696721059
Issue Date:
DOI: https://doi.org/10.1023/A:1026696721059